Therapeutic potential of adipose-derived stromal cells in age-related osteoporosis

Abstract

a b s t r a c tAdipose-derived stromal cells (ASCs) are increasingly being used for orthopedic-based tissue engineering approaches due to their ability to readily undergo osteogenic differentiation. In the present study, we used in vitro and in vivo approaches to evaluate the use of ASCs as a treatment strategy for age-related osteoporosis. Molecular, histological and micro-computed tomography (micro-CT) based approaches confirmed that ASCs isolated from 18-week-old osteoporotic senescence-accelerated mice (SAMP6) were capable of undergoing osteogenesis when cultured in either silk fibroin (SF) scaffolds or scaffold-free microtissues (ASC-MT). A single intratibial injection of CM-Dil-labeled isogeneic ASCs or ASC-MT into SAMP6 recipients significantly improved trabecular bone quality after 6 weeks in comparison to untreated contralateral bones, as determined by micro-CT. Injected ASCs could be observed in paraffin wax bone sections at 24 h and 6 weeks post treatment and induced a significant increase in several molecular markers of bone turnover. Furthermore, a significant improvement in the osteogenic potential of osteoporotic patient-derived human bone marrow stromal cells (BMSCs) was observed when differentiated in conditioned culture media harvested from osteoporotic patient-derived human ASCs. These findings therefore support the use of ASCs as an autologous cell-based approach for the treatment of osteoporosis.

The Treatment Efficacy of Bone Tissue Engineering Strategy for Repairing Segmental Bone Defects Under Osteoporotic Conditions

“…By injecting autologous BMSCs or adipose derived stem cells into local sites of osteoporotic models, bone mass and bone density at the injected site has been shown to be enhanced. 5,6,41,42 Our study demonstrated the potential of allogeneic fetal BMSCs in bone regeneration. Future studies should investigate the potential of local injection of these cells in the treatment of osteoporosis.…”

Osteoporosis: the current status of mesenchymal stem cell-based therapy

“…For application in cell therapy for osteoporosis, AD-MSCs were reported to function as an effective autologous cell-based approach for the treatment of osteoporosis. SAMP6 osteoporosis mice showed significant improvement in several trabecular bone parameters after a single intratibial transplantation of isogenic AD-MSCs [136]. A preclinical study of the in vivo function of human AD-MSCs by Cho et al revealed that human AD-MSCs could prevent OVX-induced bone loss in nude mice over 8 weeks, even though there was no evidence of long-term engraftment of infused human AD-MSCs in the bone of recipient mice [137].…”

Identification and Characterization of Long Non-Coding RNAs in Osteogenic Differentiation of Human Adipose-Derived Stem Cells

“…Recently, adipose-derived stem cells (ASCs) have been studied extensively as an alternative cell source to BMSCs due to their widespread sources, easy access and multipotency [3, 8]. More importantly, ASCs isolated from aged or osteoporotic humans and animals maintain their osteogenic differentiation capability, making them more promising for autologous cell-based therapy for osteoporosis [9-11]. Their osteogenic differentiation is regulated at transcriptional, post-transcriptional and epigenetic levels.…”